65,437 trials
Measles · Mumps · Rubella
Primary: Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL — 97.3; 93.0 Percentage of participants — p=<0.001
Sepsis · Septic Shock · Hypotension
Primary: Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients — 0; 0; 0 participants
Cystic Fibrosis
Primary: Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Evaluable Analysis Set) — 58.2 percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.060; 0.088; 0.088; 0.081 Liter — p=<0.0001
Tourette Syndrome
Primary: The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS) — 6.2; 10.5; 10.2 units on a scale
Heart Failure
Primary: Safety of Single Ascending Doses of GGF2 Via an Assessment of the Toxicology Profile as Measured by Treatment Emergent Adverse Events (TEAEs) — 6; 4; 4; 2 participants
Glaucoma · Ocular Hypertension · Open-angle Glaucoma
Primary: Change in IOP at the Final Visit From Prior Brimonidine 0.2%/Timolol 0.5% Fixed Combination (COMBIGAN®) Therapy (i.e. From Baseline) — 22.24; -2.24 mmHg
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — -0.05; -0.81 Percentage of HbA1c in the blood — p=<0.0001
Chronic Anal Fissure
Primary: Change From Baseline in Average of Worst Anal Pain Associated With or Following Defaecation for Week 4 (for the 7 Treatment Days Immediately Preceding the Week 4 Visit)…
Obese · Growth Hormone Secretion Abnormality
Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02
Peripheral Arterial Disease
Primary: Reporting of Adverse Events During 11 Week Treatment Period. — 9; 12; 14; 2 participants
Asthma
Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…
Follicular Lymphoma · Small Lymphocytic Lymphoma · Marginal Zone Lymphoma
Primary: Overall Response Rate of of Participants to Imexon in the Treatment of Relapsed/Refractory Indolent and Aggressive Lymphomas — 30 percentage of participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — 0.33; -0.80; -0.55 Percentage of HbA1c in the blood — p=<0.0001
Death, Sudden, Cardiac · Ventricular Fibrillation · Tachycardia, Ventricular
Primary: Number of Participants Without Defibrillation — 94; 97 participants